Caladrius Biosciences Inc expected to post a loss of 14  cents a share - Earnings Preview

Lisata Therapeutics

11/03/2022 23:26

* Caladrius Biosciences Inc  CLBS.OQ   CLBS.O  is expected
to show
no change in quarterly revenue when it reports  results on March
11 (estimated). 
    * ​Refinitiv's mean analyst estimate for Caladrius
Biosciences Inc
is for a loss of 14 cents per share. For the same quarter last
year, the company reported a loss of 28 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Caladrius
Biosciences Inc is $9​, above​ its last closing price of $0.68.
​​​

This summary was machine generated March 11 at 23:26 GMT.  All
figures in US dollars  unless otherwise stated